Renal Cancer - Results from #760

Real-time Estimation of Nephron Activity with a Linear Measurement System (RENAL-MS) Predicts Postoperative eGFR. September 7, 2023

Kidney function and risk of Renal Cell Carcinoma. September 7, 2023

Perioperative, functional, and oncological outcomes of robotic vs. laparoscopic partial nephrectomy for complex renal tumors (RENAL score ≥7): an evidence-based analysis. September 6, 2023

The Utility of Renal Mass Biopsy in Large Renal Masses. September 6, 2023

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. September 5, 2023

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. September 5, 2023

Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy. September 4, 2023

A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors. September 4, 2023

Pre-operative Plasma Fibrinogen Level as a Potential Predictor of Pathological T3 Upstaging in Clinically Localized Renal Cell Carcinoma. September 1, 2023

T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective Multi-institute Results. September 1, 2023

Bioinformatic Analysis on the Prognostic Value of Neurotransmitter Receptor-Related Genes in Kidney Renal Clear Cell Carcinoma. August 31, 2023

Web-grading-a tool to test personal grading of renal and prostate cancer. August 31, 2023

En-Bloc Resection of Renal Cell Carcinoma With Tumor Thrombus Propagating Into the Intrapericardial Inferior Vena Cava: Efficacy and Safety of Transabdominal Approach. August 31, 2023

Lifetime body weight trajectories and risk of renal cell cancer: a large US prospective cohort study. August 30, 2023

Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma. August 30, 2023

Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN. August 29, 2023

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. August 29, 2023

A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R-COS). August 29, 2023

Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis. August 28, 2023

Patient-specific simulations and navigation systems for partial nephrectomy. August 28, 2023

Page 39 of 456